In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Pharma May Be Big Player in Follow-On Biologics Market

Executive Summary

This article is a reprint from the April 2008 issue of The RPM Report. As Congress works on an approval pathway for follow-on biologics, generic drug companies are jockeying for investors' attention. But given that most generic manufacturers may be ill-equipped to handle the development of follow-on proteins, some analysts think the real opportunity is where you'd least expect: inside Big Pharma and biotech.
Advertisement

Related Content

Merck’s Ambitious Plans For Follow-On Biologics
Turning Back the Clock: Drug Approvals Hit 25 Year Low
Betting Generic: Part D, Patents and Proteins Drive Investment Surge
Flubbing the FOBs Opportunity: Follow-on Biologics Winners & Losers
Biogenerics Are Happening: Slowly, Product-By-Product
Biogenerics: A Step Closer
Biogenerics Are Coming and They're Not the Generics We Know

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003111

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel